{"DataElement":{"publicId":"5783388","version":"1","preferredName":"Chemotherapy Mercaptopurine Methotrexate Agent Comprehension Of Taking Purpose Six Mercaptopurine And Methotrexate Take Purpose Type","preferredDefinition":"Information related to the understanding of the purpose of taking 6MP and Methotrexate.","longName":"5782837v1.0:5783382v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"5782837","version":"1","preferredName":"Chemotherapy Mercaptopurine Methotrexate Agent Comprehension Of Taking Purpose","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases._A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)_An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._What something is used for; reason or intention._An ability to understand the meaning or importance of something (or the knowledge acquired as a result)._As pertains to a medication: ingest, inhale, instill, or inject.","longName":"5782078v1.0:5782835v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"5782078","version":"1","preferredName":"Chemotherapy Mercaptopurine Methotrexate Agent","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.:A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04):An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C15632:C195:C642:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Mercaptopurine","conceptCode":"C195","definition":"A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E11966F-A200-17A2-E053-F662850A1F89","latestVersionIndicator":"Yes","beginDate":"2017-04-26","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-26","modifiedBy":"ONEDATA","dateModified":"2017-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5782835","version":"1","preferredName":"Comprehension Take Purpose","preferredDefinition":"An ability to understand the meaning or importance of something (or the knowledge acquired as a result).:As pertains to a medication: ingest, inhale, instill, or inject.:What something is used for; reason or intention.","longName":"C86022:C65105:C25634","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Comprehension","conceptCode":"C86022","definition":"An ability to understand the meaning or importance of something (or the knowledge acquired as a result).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Take","conceptCode":"C65105","definition":"As pertains to a medication: ingest, inhale, instill, or inject.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Purpose","conceptCode":"C25634","definition":"What something is used for; reason or intention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E274EFA-3626-0742-E053-F662850A587A","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E274EFA-3637-0742-E053-F662850A587A","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"MORENOC","dateModified":"2017-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5783382","version":"1","preferredName":"Six Mercaptopurine And Methotrexate Take Purpose Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities._A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one._A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)_An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear._What something is used for; reason or intention._As pertains to a medication: ingest, inhale, instill, or inject._What something is used for; reason or intention.","longName":"5783382v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E289352-88CE-29FF-E053-F662850AC324","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"},{"value":"I don't really know","valueDescription":"Does Not Know","ValueMeaning":{"publicId":"3247120","version":"1","preferredName":"Does Not Know","longName":"3247120","preferredDefinition":"The answer is not known by the person answering.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Does Not Know","conceptCode":"C67142","definition":"The answer is not known by the person answering.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6531898-A7F3-5C37-E040-BB89AD43329F","latestVersionIndicator":"Yes","beginDate":"2011-06-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-06-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E289352-88D8-29FF-E053-F662850AC324","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"},{"value":"Because the doctor/nurse tells me to take it","valueDescription":"Due To Doctor Nurse Statement To Take","ValueMeaning":{"publicId":"5783383","version":"1","preferredName":"Due To Doctor Nurse Statement To Take","longName":"5783383","preferredDefinition":"Caused by or resulting from.: A courtesy title for a person who has received a doctorate degree or who practices medicine.: A professional healthcare provider who has graduated from an accredited nursing program, has passed the state exam for licensure, and been registered or licensed to practice by a state authority.  Nurses are educationally prepared as functional (LPN/LVN) or professional (RN).: A verbal and/or written message that asserts, affirms, or declares something.: Used as a function word to indicate direction, purpose, or movement.: As pertains to a medication: ingest, inhale, instill, or inject.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Due To","conceptCode":"C89272","definition":"Caused by or resulting from.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Doctor","conceptCode":"C69164","definition":"A courtesy title for a person who has received a doctorate degree or who practices medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Nurse","conceptCode":"C20821","definition":"A professional healthcare provider who has graduated from an accredited nursing program, has passed the state exam for licensure, and been registered or licensed to practice by a state authority.  Nurses are educationally prepared as functional (LPN/LVN) or professional (RN).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Statement","conceptCode":"C49154","definition":"A verbal and/or written message that asserts, affirms, or declares something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Take","conceptCode":"C65105","definition":"As pertains to a medication: ingest, inhale, instill, or inject.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E289352-88EA-29FF-E053-F662850AC324","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E289352-8903-29FF-E053-F662850AC324","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"},{"value":"To fight or destroy cancer or leukemia cells","valueDescription":"To Resistance Process Or Destruction Malignant Neoplasm Or Leukemia Cell","ValueMeaning":{"publicId":"5783384","version":"1","preferredName":"To Resistance Process Or Destruction Malignant Neoplasm Or Leukemia Cell","longName":"5783384","preferredDefinition":"Used as a function word to indicate direction, purpose, or movement.: A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: The act of destroying; demolition or annihilation.: A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.: Any small compartment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Resistance Process","conceptCode":"C41546","definition":"A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Destruction","conceptCode":"C62100","definition":"The act of destroying; demolition or annihilation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cell","conceptCode":"C48694","definition":"Any small compartment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E289352-8916-29FF-E053-F662850AC324","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E289352-892F-29FF-E053-F662850AC324","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"},{"value":"Because it is part of my treatment","valueDescription":"Due To Part Therapeutic Procedure","ValueMeaning":{"publicId":"5783385","version":"1","preferredName":"Due To Part Therapeutic Procedure","longName":"5783385","preferredDefinition":"Caused by or resulting from.: One of the portions into which something is regarded as divided and which together constitute a whole.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Due To","conceptCode":"C89272","definition":"Caused by or resulting from.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Part","conceptCode":"C45313","definition":"One of the portions into which something is regarded as divided and which together constitute a whole.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E289352-893D-29FF-E053-F662850AC324","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E289352-8956-29FF-E053-F662850AC324","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"},{"value":"To fight or prevent infection","valueDescription":"To Resistance Process Or Preventive Infection","ValueMeaning":{"publicId":"5783386","version":"1","preferredName":"To Resistance Process Or Preventive Infection","longName":"5783386","preferredDefinition":"Used as a function word to indicate direction, purpose, or movement.: A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Used to prevent disease.: The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Resistance Process","conceptCode":"C41546","definition":"A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Preventive","conceptCode":"C28005","definition":"Evidence of preventive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Infection","conceptCode":"C128320","definition":"The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E289352-8966-29FF-E053-F662850AC324","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E289352-897F-29FF-E053-F662850AC324","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"},{"value":"To keep the blood counts low","valueDescription":"To Retain Blood Cell Count Low","ValueMeaning":{"publicId":"5783387","version":"1","preferredName":"To Retain Blood Cell Count Low","longName":"5783387","preferredDefinition":"Used as a function word to indicate direction, purpose, or movement.: To maintain possession of something.: A test to check the number of red blood cells, white blood cells, and platelets in a sample of blood.: A minimum level or position or degree; less than normal in degree, intensity or amount.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Retain","conceptCode":"C99569","definition":"To maintain possession of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Blood Cell Count","conceptCode":"C28133","definition":"The determination of the number of red blood cells, white blood cells, and platelets in a biospecimen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Low","conceptCode":"C54722","definition":"A minimum level or position or degree; less than normal in degree, intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E289352-898E-29FF-E053-F662850AC324","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4E289352-89A7-29FF-E053-F662850AC324","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5783381","version":"1","preferredName":"Six Mercaptopurine And Methotrexate Take Purpose Type","preferredDefinition":"A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.:A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04):An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.:An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.:As pertains to a medication: ingest, inhale, instill, or inject.:What something is used for; reason or intention.:Something distinguishable as an identifiable class based on common qualities.","longName":"5783381v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Six","conceptCode":"C66837","definition":"A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Mercaptopurine","conceptCode":"C195","definition":"A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Take","conceptCode":"C65105","definition":"As pertains to a medication: ingest, inhale, instill, or inject.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Purpose","conceptCode":"C25634","definition":"What something is used for; reason or intention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E289352-88A6-29FF-E053-F662850AC324","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"ONEDATA","dateModified":"2017-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E289352-88B7-29FF-E053-F662850AC324","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"MORENOC","dateModified":"2017-07-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What is your understanding of","type":"Preferred Question Text","description":"What is your understanding of purpose of taking 6MP and Methotrexate?","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E28B0FC-2CB4-0462-E053-F662850AB06B","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-04-27","modifiedBy":"MORENOC","dateModified":"2017-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}